|Chemical and physical data|
|Molar mass||475.470143 g/mol|
|3D model (JSmol)|
Trelagliptin (Zafatek) is a pharmaceutical drug used for the treatment of type 2 diabetes (diabetes mellitus).
It is a highly selective dipeptidyl peptidase-4 inhibitor that is typically used as an add on treatment when the first line treatment of metformin is not achieving the expected glycemic goals; though it has been approved for use as a first line treatment when metformin cannot be used.
Formulated as the salt trelagliptin succinate, it was approved for use in Japan in March 2015. Takeda, the company that developed trelagliptin, chose to not get approval for the drug in the USA and EU. The licensing rights that Takeda purchased from Furiex Pharmaceuticals for DPP-4 inhibitors included a clause specific to development of this drug in the USA and EU. The clause required that all services done for phase II and phase III clinical studies in the USA and EU be purchased through Furiex. Takeda chose to cease development of this drug in the USA and EU because of the high costs quoted by Furiex for these services. Gliptins have been on the market since 2006 and there are 8 gliptins currently registered as drugs (worldwide). Gliptins are an emerging market and are thus being developed at an increasing rate; there are currently two gliptins in advanced stages of development that are expected to be on the market in the coming year.
Gliptins are thought to have cardiovascular protective abilities though the extent of these effects is still being studied. They are also being studied for the ability that this class of drugs has at promoting B-cell survival.
Administration and dosing
Similar drugs in the same class as trelagliptin are administered once daily while trelagliptin is administered once weekly. Alogliptin (Nesina) is the other major DPP-4 inhibitor on the market. It is also owned by Takeda and is administered once daily. A dosing of once per week is advantageous as a reduction in the frequency of required dosing is known to increase patient compliance.
- McKeage, Kate (2015-06-27). "Trelagliptin: First Global Approval". Drugs. 75 (10): 1161–1164. doi:10.1007/s40265-015-0431-9. ISSN 0012-6667. PMID 26115728.
- Inagaki, Nobuya; Onouchi, Hitoshi; Sano, Hiroki; Funao, Nobuo; Kuroda, Shingo; Kaku, Kohei. "SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial". The Lancet Diabetes & Endocrinology. 2 (2): 125–132. doi:10.1016/s2213-8587(13)70149-9.
- "New Drug Application Approval of Zafatek® Tablets for the treatment of Type 2 Diabetes in Japan | Takeda Pharmaceutical Company Limited". www.takeda.com. Retrieved 2015-11-13.
- Cahn, Avivit; Raz, Itamar (2013-06-01). "Emerging gliptins for type 2 diabetes". Expert Opinion on Emerging Drugs. 18 (2): 245–258. doi:10.1517/14728214.2013.807796. ISSN 1472-8214. PMID 23725569.
- Inagaki, Nobuya; Onouchi, Hitoshi; Maezawa, Hideaki; Kuroda, Shingo; Kaku, Kohei (2015). "Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study". The Lancet Diabetes & Endocrinology. 3 (3): 191–197. doi:10.1016/s2213-8587(14)70251-7. PMID 25609193.